• Actinium Initiates Patient Enrollment in Iomab-ACT Trial americanpharmaceuticalreview
    April 01, 2021
    Actinium Pharmaceuticals announced its collaborator, Memorial Sloan Kettering Cancer Center (MSK), has commenced patient enrollment in the Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK's CD19 targeted ...
PharmaSources Customer Service